Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-138500 · Präparat HOS-098200
17 PROTON PUMP INHIBITORS Dexlansoprazole Based on theoretical Symtuza can be co-administered Esomeprazole considerations, no mechanistic with proton pump inhibitors Lansoprazole interaction is expected. without dose adjustments. Omeprazole Pantoprazole Rabeprazole SEDATIVES/HYPNOTICS Buspirone Based on theoretical considerations Clinical monitoring is Clorazepate DRV/COBI is expected to increase recommended when Diazepam these sedative/hypnotic plasma co-administering Symtuza with Estazolam concentrations. these sedatives/hypnotics and a Flurazepam (CYP3A inhibition) lower dose of the Midazolam (parenteral) sedative/hypnotic should be Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) estazolam (HOS-086165) esomeprazole (HOS-087944) pantoprazole (HOS-085167) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) dexlansoprazole (HOS-138501) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d66918b1ab817bed50d64727b6ed8e70c3661e6e6c213975acff37740c998350 · Zeichen 42940–44015 im Abschnitt